EcoDrugPlus

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSOCUG00000002303
Gene Symbol: PARP2
2 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSOCUG00000021270
Gene Symbol: PARP3
3 Cross references
198 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOCUG00000015293
Gene Symbol: PORCN
2 Cross references
265 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOCUG00000009543
Gene Symbol: KCNMA1
2 Cross references
284 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSOCUG00000006168
Gene Symbol: KCNN4
2 Cross references
187 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSOCUG00000010416
Gene Symbol: KCNJ2
3 Cross references
277 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSOCUG00000024206
Gene Symbol: KCNJ3
3 Cross references
219 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSOCUG00000015565
Gene Symbol: KCNJ5
3 Cross references
205 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSOCUG00000008629
Gene Symbol: KCNK2
3 Cross references
280 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSOCUG00000025172
Gene Symbol: KCNK3
2 Cross references
203 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSOCUG00000013532
Gene Symbol: KCNK9
2 Cross references
211 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSOCUG00000000674
Gene Symbol: KCNA5
3 Cross references
169 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).